A Houston startup has launched to keep an eye on your AC to predict and prevent outages and issues. Photo courtesy of SmartAC.com

It can get hot as Hades in Houston during the summer, and a new Houston startup is using machine learning and technology to ensure that users can count on their air conditioning units to stay up and running during the heat.

Houston-based SmartAC.com has emerged from stealth mode with $10 million in funding from a series A investment round. The company's technology focuses on maintaining air conditioning and heating (HVAC) health before a major service issue occurs.

"Over 70 million homes have central air in the U.S., making indoor comfort a regular way of life. People don't often think about their HVAC systems, taking it for granted, until the day the AC or heat goes out," says Josh Teekell, CEO and founder of SmartAC.com, in a news release. "These systems require regular upkeep, and when they aren't maintained, costs can get out of hand. SmartAC.com's offer is simple; we care about your AC so you don't have to."

The company's technology combines three hardware sensors — which users can install themselves — and machine learning software to analyze data to predict service issues. The comfort sensor monitors the temperature of the air coming out of the unit, the filter sensor tracks the lifespan of air filters by tracking pressure and airflow, and the water sensor protects against leaks and clogs.


The three SmartAC.com sensors are magnetic and easy to install. Photo courtesy of SmartAC.com

All three sensors are linked by SmartAC.com Hub, which sends data from the sensors to the cloud and the SmartAC.com app to translate the data into recommendations to help users reduce costs and get ahead of issues.

"The average AC replacement cost is $7,500 — an expense that can be a huge burden on homeowners. Caring for these assets is inconvenient and oftentimes confusing, resulting in 80 percent of homeowners skipping the recommended maintenance on their AC systems," says Andrew Fuselier, SmartAC.com's COO, in a news release. "It's time to digitize the AC ownership experience to solve a decades old problem. SmartAC.com was formed in stealth mode with feedback from thousands of homeowners, so we're thrilled to finally show the world what we've built."

In addition to working directly with consumers, SmartAC.com has teamed up with HVAC service providers.

"SmartAC.com is a total game-changer," says David Lewis of Mission AC in a news release. "Our clients love the additional transparency and the technology allows us to improve our service speed and quality because, for the first time, we have real-time data on the systems we service."

The data from the sensors is analyzed and sent to users via the smart phone app. Photo courtesy of SmartAC.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”